Lexaria Bioscience (LEXX) Convertible Debt (2016 - 2017)
Lexaria Bioscience (LEXX) posted Convertible Debt of $45000.0 for Q2 2017, little changed sequentially from $45000.0 in Q1 2017, and little changed YoY from $45000.0 in Q2 2016.
Lexaria Bioscience (LEXX) Convertible Debt (2016 - 2017) Analysis & Trends
Lexaria Bioscience has reported Convertible Debt for 2 years, with the latest figure at $45000.0 in Q2 2017.
- Quarterly Convertible Debt changed 0.0% year-over-year to $45000.0 in Q2 2017, while the trailing twelve-month figure through May 2017 was $45000.0 (changed 0.0% YoY) and the FY2016 annual result came in at $45000.0, changed N/A from the prior year.
- Convertible Debt held at $45000.0 in Q2 2017 per LEXX's latest filing, from $45000.0 in the prior quarter.
- Over five years, Convertible Debt peaked at $45000.0 in Q2 2016 and troughed at $45000.0 in Q2 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2017 | 45,000.00 |
| Feb 28, 2017 | 45,000.00 |
| Nov 30, 2016 | 45,000.00 |
| Aug 31, 2016 | 45,000.00 |
| May 31, 2016 | 45,000.00 |